Lutetium Lu 177 AB-3PRGD2

Preferred Label : Lutetium Lu 177 AB-3PRGD2;

NCIt synonyms : 177Lu-3PRGD2; 177Lu-AB-3PRGD2;

NCIt definition : A radiopharmaceutical agent comprised of a pegylated cyclic arginine-glycine-aspartic acid (RGD) dimer (PRGD2) labeled with lutetium Lu 177, with potential antineoplastic activity against alphaVbeta3 integrin-expressing tumor cells. Upon administration of lutetium Lu 177 AB-3PRGD2, the RGD moiety binds to alphaVbeta3 integrin on alphaVbeta3 integrin-expressing tumor cells. The tumor cells can be eradicated upon direct cytotoxicity through beta radiation. AlphaVbeta3 integrin, a member of the integrin receptor family, is overexpressed on certain tumor cells and tumor endothelial cells while minimally or not expressed on healthy, normal cells; this receptor plays a key role in angiogenesis, tumor proliferation and survival.;

NCI Metathesaurus CUI : CL1772608;

Details

Origin ID

C184308;

UMLS CUI

C3883932;

Automatic exact mappings (from CISMeF team)
- 177Lu-3PRGD2 [MeSH concept]
- 177Lu-3PRGD2 [MeSH Supplementary Concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- 177Lu-3PRGD2 [MeSH Supplementary Concept]
- 177Lu-3PRGD2 [MeSH concept]
concept_is_in_subset
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Integrin AlphaV/Beta3 [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients